FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development ; volume:15 ; number:1 ; day:3 ; month:9 ; year:2020 ; pages:1-8 ; date:12.2020
Orphanet journal of rare diseases ; 15, Heft 1 (3.9.2020), 1-8, 12.2020
- Urheber
-
Miller, Kathleen L.
Mueller, Christine
Liu, Gumei
Miller Needleman, Katherine I.
Maynard, Janet
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-020-01514-5
- URN
-
urn:nbn:de:101:1-2020102420120745024831
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 01.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miller, Kathleen L.
- Mueller, Christine
- Liu, Gumei
- Miller Needleman, Katherine I.
- Maynard, Janet
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA
FDA
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA
FDA
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA